Although the collective results suggest a clinical benefit for trastuzumab, this antibody, administered per currently approved protocols, only eradicates the disease in approximately 50% of patients with HER2-positive early BC and cannot cure those with HER2-positive metastatic tumors (reviewed in [7]) . This evidence concerns the gene ERBB2 and breast cancer.